Country of origin: UK
Specialists should not stop prescribing sunitinib for people who were already taking it when the guidance was issued. These people should be able to carry on taking sunitinib until they and their specialist decide that it is the right time to stop treatment.
NICE has been appraising the use of bevacizumab, sorafenib, sunitinib and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma.
Following the independent advisory Committee meeting on 14 January 2009 NICE has decided to split this appraisal in two in order to get guidance out to the NHS as quickly as possible.
NICE is also appraising the use of bevacizumab, sorafenib and temsirolimus for first-line treatment options for advanced and/or metastatic renal cell carcinoma and the two drugs also licensed for second-line treatment of advanced or metastatic renal cell carcinoma, sorafenib and sunitinib, guidance is expected to be published later this year.
The guidance is available online.
inPractice® Oncology July 2018
Cancer Research Network Measures March 2018
Orlive Surgical Broadcasts February 2018
Cancer.net mobile by ASCO January 2018
Chemo Calendar January 2018
Cancer Navigator January 2018
Oncology Nurse Advisor January 2018
Breast Cancer Survivor January 2018
Cancer Emergency Response Tool January 2018